The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Abstract
We recently reported that naltrexone blocks antidepressant effects of ketamine in humans, indicating that antidepressant effects of ketamine require opioid receptor activation. However, it is unknown if opioid receptors are also involved in ketamine's antisuicidality effects. Here, in a secondary analysis of our recent clinical trial, we test whether naltrexone attenuates antisuicidality effects of ketamine. Participants were pretreated with naltrexone or placebo prior to intravenous ketamine in a double-blinded crossover design. Suicidality was measured with the Hamilton Depression Rating Scale item 3, Montgomery-Åsberg Depression Rating Scale item 10, and Columbia Suicide Severity Rating Scale. In the 12 participants who completed naltrexone and placebo conditions, naltrexone attenuated the antisuicidality effects of ketamine on all three suicidality scales/subscales (linear mixed model, fixed pretreatment effect, p < 0.01). Results indicate that opioid receptor activation plays a significant role in the antisuicidality effects of ketamine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been proposed that ketamine’s anti-suicidal and antidepressant effects may depend on activation of the opioid system, since pre-treatment with naltrexone (an opioid receptor antagonist) attenuated these effects in depressed patients.128,129”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [128]
In the citing paper
“Some (but not all) studies have demonstrated attenuation of ketamine’s AD efficacy with coadministration of naltrexone, a non-selective opioid receptor antagonist, again necessitating further replication [84,85].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [84]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(2001) · PubMed · Cited by 780
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Stone, D. M., Simon, T. R., Fowler, K. A., Kegler, S. R., Yuan, K., Holland, K. M., Ivey-Stephenson, A. Z., & Crosby, A. E. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6722a1 · Cited by 634
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Self-citation
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“5 mg/kg) in adults (N530) with TRD (39, 40).”
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“In humans, opioid receptors have been implicated in ketamine’s antidepressant efficacy [49, 50] and hypothesized to underlie risks associated with its abuse liability [16].”
BackgroundAday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Self-citation
Metadata
- Authors
- Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F.
- Affiliations
- Stanford Medicine (US)
- Palo Alto University (US)
- Corresponding author
- Williams, Nolan R.
- Schatzberg, Alan F.
- Venue
- Molecular Psychiatry
- Published
- 2019-08-29
- Volume
- 24
- Issue
- 12
- Pages
- 1779-1786
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2970951648
- Cited by
- 174
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 35 · 2023: 19 · 2022: 24 · 2021: 22 · 2020: 32 · 2019: 1
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (UL1 TR 001085)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, naltrexone, opioid antagonism, antidepressant effects, suicidality, opioid receptor activation, depression, suicide risk
- MeSH terms
- Adult, Antidepressive Agents, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Psychiatric Status Rating Scales, Receptors, Opioid, Suicide, Treatment Outcome, Cross-Over Studies, Excitatory Amino Acid Antagonists, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. https://app.cochat.ai/papers/10.1038/s41380-019-0503-4
- The paper
- Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019). Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0503-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.